AIIMS Patna has developed an indigenous neurosurgical device designed to improve the safety and precision of complex brain surgeries. The innovative equipment functions as both a floating and fixed tubular retractor, allowing neurosurgeons to adapt the device according to the complexity and location of the procedure while minimizing damage to healthy brain tissue.

According to the institute, the device can be seamlessly integrated with advanced neuronavigation systems and robotic surgical platforms, enabling surgeons to achieve a precision of 1–2 millimetres during delicate neurosurgical procedures. Such accuracy is critical when operating near vital brain structures responsible for movement, speech and cognition.

Unlike conventional brain retractors, the newly developed system provides greater flexibility during surgery by allowing controlled access to deep seated brain lesions while reducing pressure on surrounding tissues. The innovation is expected to support procedures involving brain tumours, intracerebral haemorrhages, vascular malformations and other complex neurological conditions.

Neurosurgery is increasingly adopting technologies such as robotics, neuronavigation, intraoperative imaging and minimally invasive surgical tools to improve clinical outcomes and shorten recovery time. Experts believe indigenous innovations can significantly reduce dependence on imported surgical equipment while making advanced technologies more accessible and affordable for Indian hospitals.

Brain disorders remain a major public health challenge globally. According to WHO, neurological disorders account for one of the leading causes of disability and are responsible for a significant proportion of premature deaths worldwide, highlighting the need for continued innovation in neurosurgical care.

Healthcare experts have welcomed AIIMS Patna’s development, stating that homegrown medical technologies can strengthen India’s medtech ecosystem, improve surgical outcomes and support the country’s vision of becoming a global hub for affordable healthcare innovation. The institute is expected to undertake further clinical validation before wider adoption of the device across neurosurgical centres.